Articles with "durva" as a keyword



A pilot presurgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients (pts) with high-risk muscle-invasive bladder carcinoma (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy (NAC).

Sign Up to like & get
recommendations!
Published in 2019 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2019.37.15_suppl.4551

Abstract: 4551 Background: In MIBC pts, especially in those with high risk features including lymphovascular invasion, hydronephrosis, T3b disease, or variant histology, cisplatin-based NAC followed by cystectomy improves overall survival as compared with cystectomy alone. However,… read more here.

Keywords: high risk; durva; ineligible cisplatin; cisplatin based ... See more keywords

Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK+ non-small cell lung cancer (NSCLC).

Sign Up to like & get
recommendations!
Published in 2024 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2024.42.16_suppl.8013

Abstract: 8013 Background: For patients (pts) with unresectable locally-advanced NSCLC, standard of care involves durva consolidation after concurrent CRT, although its benefit in ALK+ tumors is unclear. The ALINA trial demonstrated adjuvant efficacy of alectinib in… read more here.

Keywords: durva; alk tki; consolidation; alk nsclc ... See more keywords

Peripheral biomarker analysis in patients with advanced urothelial carcinoma (UC) after platinum chemotherapy treated with cabozantinib (CABO) plus durvalumab (DURVA): Preliminary analysis from the phase 2 ARCADIA trial.

Sign Up to like & get
recommendations!
Published in 2024 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2024.42.4_suppl.684

Abstract: 684 Background: Preliminary results of the interim analysis of the ARCADIA trial have shown that combining multitargeted receptor tyrosine kinase inhibitor CABO with the checkpoint inhibitor DURVA has promising activity and a manageable safety profile… read more here.

Keywords: durva; hla; analysis; trial ... See more keywords